AirSculpt Technologies Q3 2026: Volumes Fall, Guidance Cut

As seen on the 24/7 Wall St. homepage on November 6, 2026.

AIRS Airsculpt Technologies
Q3 2026
EPS
-$0.08
est -$0.03 -166.7%
Revenue
$32M
est $35M -7.5%

Management cut full-year revenue guidance to $144 million to $146 million from $151 million to $157 million, assuming the 9.6% same-store case volume decline holds through year-end. Adjusted EBITDA shrank to $393,000, leaving almost no cushion.

Continue ReadingShow less

AirSculpt Technologies reported third-quarter 2026 revenue of $31.94 million, down 8.7% from a year earlier and missing expectations. The adjusted loss per share of $0.08 also came in missing expectations, one of the company's sharpest quarterly earnings misses in recent periods.

The root cause was a steep drop in patient traffic. Total cases fell 9.6% on a same-store basis, overwhelming a modest improvement in revenue per case to $12,865. Pricing gains alone cannot hold the revenue line when volume shrinks that fast.

Profitability essentially evaporated, with adjusted EBITDA down to $393,000 from $3.04 million a year ago. Rising SG&A costs compounded the pressure, squeezing adjusted EBITDA margin to 1.2%.

Sponsored

Management cut full-year 2026 revenue guidance to $144 million to $146 million from the prior $151 million to $157 million, and trimmed adjusted EBITDA guidance as well. The revised outlook assumes the 9.6% same-store volume decline persists through year-end, a direct acknowledgment that the slowdown is not expected to self-correct quickly.

CEO Yogi Jashnani said results were "below expectations" and that management is "addressing them with a sense of urgency." He pointed to roughly 250 GLP-1-related procedures in the quarter as a nascent growth avenue, and noted the company refinanced its term loan after the quarter ended, extending debt maturity to 2031.

Mentioned: AIRS